Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.…
Vivos Therapeutics Inc (VVOS) (Q3 2026) Earnings Call Highlights: Cost Cuts, Payer ...
Vivos Therapeutics (NASDAQ: VVOS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 268 employees.
The shares were at 0.0540 USD on 20 November 2026, down 97.7% over 52 weeks. Its 52-week range is 0.0501 USD to 2.720 USD: the price is 98.0% below the high and 7.8% above the low.
Its market capitalisation is 1.83M USD.
Vivos Therapeutics reports an operating margin of -107.9% and revenue up 34.9% year over year.
Its debt exceeds its cash by 10.73M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 31 March 2027.